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quences including phrenic nerve stimulation, lead dislodge-
ment/dysfunction, and infection (upgrade: 3.5 % versus de 
novo: 4.9 %).
Conclusion Upgrade procedures are not more complex 
nor associated with more complications than de novo CRT 
implantations.
Keywords CRT · Upgrade · Complication
Introduction
Cardiac resynchronisation therapy (CRT) is most effec-
tive in heart failure patients with left bundle branch block 
as it specifically aims to resynchronise the delayed electri-
cal activation of the left ventricle [1–2]. However, CRT is 
indicated in a much broader spectrum of patients with heart 
failure [3]. A large European survey among 141 hospitals 
demonstrated that approximately 25 % of CRT implanta-
tions are upgrade procedures [4]. Patients with an existing 
cardiac implantable electronic device (CIED) have a class 
I indication for upgrading to CRT when they experience a 
high percentage of ventricular pacing and remain in New 
York Heart Association (NYHA) class III to ambulatory 
IV with a left ventricular ejection fraction (LVEF) ≤ 35 %. 
Other reasons for upgrading to CRT include (i) worsening of 
heart failure (class) in patients with pre-existing wide QRS 
complexes, (ii) electrical remodelling due to heart failure 
or antiarrhythmic drug therapy with widening of the QRS 
complex, and (iii) evolving CRT guidelines.
Previous literature has shown that cardiac device replace-
ment or upgrade procedures are associated with more com-
plications and are more complex than de novo implantations 
due to the possibility of venous thrombosis and the risk 
of damaging or extracting old leads [5, 6]. The fear of a 
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complicated procedure might prevent upgrading to CRT in 
patients with a clear indication. Moreover, reluctance about 
the need for an upgrade procedure in the future might make 
clinicians more willing to implant a de novo CRT device 
in heart failure patients with only a class IIb indication for 
CRT but a clear indication for a conventional (single or dual 
chamber) device.
We aimed to evaluate procedural data and periprocedural 
and long-term complication rates of upgrade procedures 
compared with de novo CRT implantations in our university 
medical centre.
Method
Study population, procedure and complication data
This retrospective study analysed data from all patients 
who had undergone an upgrade procedure from a single 
or dual chamber pacemaker or implantable cardioverter 
defibrillator (ICD) to a CRT device at the University Medi-
cal Centre of Utrecht (UMCU) in the period 2006–2012. 
An equally sized reference group of de novo implantations 
was randomly constructed out of patients implanted in the 
same period (N = 358). Procedures were performed by expe-
rienced operators, defined as performing at least 75 ICD/
pacemaker implantations annually with at least one-third of 
these being CRT device implantations.
Procedural data as procedure length, radiation duration 
and hospitalisation duration were collected. Periprocedural 
complications (≤ 30 days) and long-term device-related 
complications (≤ 1 year) were divided into complications 
with and without consequences. Complications with con-
sequences were defined as those in need of invasive pro-
cedures (e.g. lead revision/replacement, extraction of the 
system, pericardiocentesis) or any other action deviating 
from standard clinical care (prolonged hospitalisation, post-
ponement of implant after start, transfer to the coronary or 
intensive care unit or the need to start anticoagulants).
Statistical analysis
Baseline characteristics of the upgrade group were com-
pared with the de novo implant group. Categorical variables 
are presented as percentages and the P-value was calculated 
using Pearson’s Chi-square test. Distribution of continuous 
variables was assessed by the Kolmogorov-Smirnov test 
for normality. If distribution was skewed, variables are pre-
sented as median with 25th to 75th percentile interquartile 
range (IQR) and the P-value was calculated by the Mann-
Whitney U test. Normally distributed variables are pre-
sented as means with a standard deviation and a P-value 
calculated by the Student’s t test. The occurrence of specific 
periprocedural complications was compared between de 
novo and upgrade procedures using a Chi-square test. The 
hazard ratio for the risk of any periprocedural complication 
with consequences for the type of procedure (upgrade ver-
sus de novo implantation) was calculated by a crude logistic 
regression analysis. To identify any confounding effect of 
baseline characteristics on the risk of periprocedural com-
plications after an upgrade procedure and de novo CRT 
implantation, multiple bivariate logistic regression analyses 
were performed, including procedure type and one baseline 
characteristic. The crude hazard ratio for procedure type and 
risk of periprocedural complications was adjusted for all 
baseline characteristic differences in a multivariable logistic 
regression analysis. The comparison of the occurrence of 
long-term complications by procedure type was performed 
by the Chi-square test. Patients with censored data due to 
loss to follow-up or death within 1 year of follow-up were 
excluded from this comparison.
Results
Patient characteristics of total population
This analysis included 134 patients who underwent an 
upgrade procedure to a CRT device and 134 randomly 
selected patients receiving a de novo CRT device. Of these 
268 patients, 264 (98.5 %) received a CRT defibrillator 
(CRT-D), three (2.2 %) patients were upgraded to a CRT 
pacemaker (CRT-P) and one (0.7 %) patient received a de 
novo CRT-P. Fifty-four (40 %) patients where upgraded 
from a double chamber device and 81 (60 %) from a single 
chamber device. Seventy-six (57 %) upgrade patients were 
paced from the right ventricle at baseline. Upgrading took 
place 57 (31–115) months after implantation of the initial 
CIED.
Baseline data are presented in Table 1. Upgrade patients 
were more often males (P = 0.011) and of older age 
(P = 0.001) than the random sample of patients receiving 
a de novo CRT implantation. They more often had isch-
aemic cardiomyopathy (P = 0.049) and a history of atrial 
fibrillation (P = 0.008) and were more often on amiodarone 
(P < 0.001) and a vitamin K antagonist (P = 0.022). No base-
line characteristic had a significant confounding effect on 
the hazard ratio for procedure type and the risk of peripro-
cedural complications.
Procedure
Procedural data are presented in Table 2. Seventy-three 
(27 %) procedures were extended by study-related LV pres-
sure (LV dP/dt max) measurements to optimise lead posi-
tions and device settings. Standard procedures had a median 
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Periprocedural complications
The periprocedural complication rate is presented in 
Table 3. In total 21 (7.8 %) patients experienced a compli-
cation with consequences. There were no significant dif-
ferences between the upgrade and the de novo group. The 
crude hazard ratio for periprocedural complications (with 
consequences) for upgrade procedures compared with de 
novo CRT implantations was 1.692 (P = 0.260) and when 
adjusted for baseline differences between the two groups it 
was 1.779 (P = 0.249) (Table 4). One patient developed acute 
decreased saturation during an upgrade procedure probably 
based on cardiac asthma. Saturation did not improve with 
pharmacological treatment or intubation, and resuscitation 
was required, which the patient did not survive. In seven 
(2.6 %) patients transvenous LV lead placement was unsuc-
cessful due to difficulty in visualising or cannulating the 
coronary sinus. Phrenic nerve stimulation was seen in 14 
length of 139 (69) minutes. Median radiation time was 25 
(20) minutes and median hospitalisation after implantation, 
including rehospitalisation for another attempt to complete 
CRT implantation after initial LV lead placement failure, 
was 2 (2) days. There were no significant differences in these 
procedural data between upgrade and de novo CRT implan-
tation procedures. At baseline, ten (8 %) patients undergo-
ing an upgrade procedure had a subclavian (or anonyma) 
vein thrombosis. In six of these patients the vein was reca-
nalised, in two a contralateral implant was chosen and in 
two patients the occlusion could be passed. In 124 (92 %) 
de novo procedures the intention was to implant three leads. 
Ten (8 %) patients did not receive a right atrial lead because 
of permanent atrial fibrillation. Of the upgrade patients 91 
(68 %) received two new leads, three leads were placed in 
16 (12 %) patients and 27 (20 %) patients only received an 
additional LV lead.
Table 1 Baseline comparison between patients receiving an upgrade to a CRT device and those receiving a de novo CRT device
Baseline characteristics Total population 
(N = 268)
Upgrade(N = 134) De novo implants 
(N = 134)
P-value
Age (years) 69(61–74) 71(63–75) 67(60–72) 0.001
Male (N(%)) 202(± 75) 110(± 82) 92(± 69) 0.011
BMI 26(24–29) 26(24–29) 26(24–30) 0.450
NYHA class (N, %)a 0.080
 I 2(1) 1(1) 1(1)
 II 36(13) 13(10) 23(17)
 III 213(80) 110(82) 103(77)
 IV 17(6) 10(8) 7(5)
Ischaemic CMP (N, %) 148(55) 82(61) 66(49) 0.049
LVEF (%) 23( ± 7) 24( ± 7) 23( ± 7) 0.239
BNP 141(68–262) 146(73–273) 130(50–226) 0.112
Atrium fibrillation (N, %) 60(22) 39(29) 21(16) 0.008
Cardiac medication(N, %)
Diuretic 231(88) 117(88) 114(87) 0.816
Beta-blocking 201(76) 100(76) 101(76) 0.940
ACE inhibiting 227(86) 110(83) 117(89) 0.158
Other medication
Amiodarone 54(21) 39(29) 15(11) < 0.001
Use of anticoagulation(N, %)
Vitamin-K antagonist 191(72) 104(78) 87(65) 0.022
Other 57(21) 23(17) 34(25) 0.101
INR (N = 191) 1.7(1.3–2.1) 1.7(1.4–2.1) 1.5(1.3–1.9) 0.053
Comorbidity
Diabetes mellitus (N, %) 62(23) 29(22) 33(25) 0.540
COPD (N, %) 34(13) 17(13) 17(13) 0.981
Renal function (eGFR) 57(19) 55(20) 59(19) 0.090
Subclavian/anonyma vein thrombosis (N, %) 11(4) 11(8) 0(0) 0.001
Time since initial CIED implantation (months) 57(31–115) – –
 ± Standard deviation deviation, range; 25th to 75th percentile inter quartile range.
ACE angiotensin I converting enzyme, BMI body mass index, BNP brain natriuretic peptide, CIED cardiac implantable electronic device, CMP 
cardiomyopathy, COPD chronic obstructive pulmonary disease, INR international normalised ratio, LVEF left ventricular ejection fraction, 
NYHA New York Heart Association, SD standard deviation.
aNYHA III and IV versus I, II
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Discussion
Our single-centre experience did not find any significant dif-
ferences in either procedure length, radiation duration, total 
hospitalisation, or in periprocedural and long-term device-
related complication rates when comparing upgrade proce-
dures with de novo CRT implantations.
Previously, the RAFT study showed that CRT-D reduced 
rates of death and hospitalisation for heart failure when 
compared with ICD therapy only. However, device-related 
hospitalisation was significantly higher for the CRT-D 
group compared with the ICD-only group [7]. The increased 
risk of complications of a triple chamber device compared 
with conventional single and dual chamber pacemakers or 
ICDs was also highlighted by a large nationwide cohort of 
5918 Danish patients who underwent a CIED implantation, 
in which patients receiving a CRT device showed the high-
est complication rate [8]. Therefore, the decision to implant 
a triple chamber device needs to be carefully considered.
For patients with a class IIb indication for CRT but a 
clear indication for a conventional ICD the alternative to 
a de novo CRT implantation is to await the potential need 
for an upgrade to CRT. However, as was shown by Poole 
et al., CRT upgrade is a high-risk procedure as well, with 
an 18.7 % risk of any complication during a follow-up of 
six months [5]. The fear of complications associated with 
an upgrade procedure might prevent the upgrade to CRT in 
patients with a clear indication. This was suggested by the 
results of Scott et al. who performed a single-centre retro-
spective observational study evaluating the implantation of 
ICDs for a period of 5 years. In this period 549 new ICDs 
were implanted of which 73 % single or dual chamber ICDs 
and 27 % CRT-D. When they applied alternative indication 
criteria (LVEF ≤ 30 %, QRS ≥ 130 ms, NYHA I–IV), 42.6 % 
of the ICD recipients met the criteria for CRT at initial 
implant. However, the upgrade rate to CRT at 5 years was 
only 5.1 % [9].
We showed a comparable complication rate between 
upgrade and de novo CRT implantation procedures. This 
is in line with the results of the European Survey which 
showed that there were no significant differences in com-
plication rates when comparing 692 upgrades with 1675 de 
novo CRT procedures at 141 centres in Europe [4]. How-
ever, this was a randomised trial and such trials commonly 
report less complications than in a real-life setting due to 
more strict patient selection and more experienced opera-
tors. On the contrary, the previously mentioned Danish 
population-based cohort of CIED implantations, including 
445 CRT-D implantations, showed that CRT upgrade proce-
dures or lead revisions were associated with more complica-
tions than CRT de novo implantations [8]. As both our study 
and the Danish cohort study reflect the results of a real-life 
setting the differences are not likely to be based on patient 
(5.3 %) patients and usually managed by adjustments in 
the pacing configuration, but in one case lead revision was 
needed shortly after implantation. Coronary sinus dissec-
tion (3 %) did not have any invasive consequences. Three 
(1.1 %) patients had a pneumothorax in need of drainage. 
Pocket haematoma was seen in 12 (4.5 %) of the total 268 
patients; of these four upgrade patients needed to be re-hos-
pitalised or needed blood transfusion.
Long-term follow-up
Long-term device-related complications are listed in 
Table 5. A total of 236 patients completed 1 year of fol-
low-up. Ten (4.2 %) patients had a long-term device-related 
complication with consequences; there was no difference 
between upgrade (3.5 %) and de novo (4.9 %) patients. Lead 
dysfunction in need of lead replacement occurred once in a 
de novo and an upgrade patient. Lead dislodgment in need 
of lead revision was seen in three de novo patients and in 
one upgrade patient. Device-related endocarditis requiring 
extraction of the system was seen once in both a de novo 
and in an upgrade patient.
Table 2 Procedural data
Procedural data 
(median, IQR)
Total Upgrade De novo P-value
Length procedure 
(min)
156(78) 145(71) 163(81) 0.062
Standard proce-
dure (N = 194)
139(69) 135(75) 142(61) 0.515
Procedure with 
LV dP/dt max 
measurementsa
187(66) 171(72) 195(42) 0.176
Radiation time 
(min)
25(20) 25(19) 25(21) 0.595
Total hospitalisa-
tion timeb (days)
2(2) 1(2) 2(2) 0.418
Leads added or 
implanted (inten-
tion to) (N, %)
< 0.001
1 27(20 %) 0(0)
2 91(68 %) 10(8 %)
3 16(12 %) 124(92 %)
N of operating 
specialistsc
1.000
N = 1 (experienced 
cardiologist)
224(85) 112(85) 112(85)






aof which 39.7 % upgrade procedures.
bstarting after implantation including additional hospitalisation for 
later LV lead placement after initial failure or re-hospitalisation due 
to implantation or device related complications.
c4 patients had missing data on implanting physician.
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selection. In our retrospective study, patient selection was 
equal for both de novo and upgrade procedures in that it fol-
lowed standard clinical care in which the benefit of CRT is 
balanced against the risk of complications. It might be that 
the operators in our tertiary centre were more experienced 
in implanting CRT devices. Although most procedures in 
the Danish cohort were also performed by operators with an 
annual volume of at least 75 ICD or pacemaker implanta-
tions, it is not clear whether the experience in implanting a 
CRT device was as high as in our centre [8]. Another point 
of concern for many clinicians is the fear of a more complex 
procedure when a single or dual chamber pacemaker or ICD 
needs to be upgraded, compared with a de novo implanta-
tion of a CRT device, due to the possibility of damaging or 
extracting old leads. Four upgrade patients experienced lead 
dysfunction after the procedure, which is comparable with 
numbers in previous literature [5, 10]. These were three old 
leads (two right atrial leads and one right ventricular lead) 
and one newly placed right atrial lead. The dysfunction of 
the old leads was seen 2–12 months after upgrade proce-
dure. Moreover, this was done due to damage to the old lead 
during the procedure in only one of 16 upgrade patients who 
received a completely new system. Therefore, our data seem 
to indicate that when an upgrade procedure is performed by 
an experienced operator the risk of damaging old leads is 
small. Furthermore, we found no significant difference in 
procedure duration comparing upgrade procedures with de 
novo implantations, but there was a slight trend towards an 
even shorter procedure length for upgrade procedures. This 
suggests comparable complexity as one would expect the 
upgrade procedure to require a smaller amount of time, as 
in most upgrades less leads are added than implanted during 
a de novo implantation. Complicating factors such as sub-
clavian vein thrombosis only slightly increased the median 
procedure duration compared with standard procedures (159 
(95) minutes versus 139 (69) minutes). Moreover, in our 
upgrade group the procedure success was 98.5 % and did 
not significantly differ for the randomly selected de novo 
CRT implantation procedures. A meta-analysis of 9082 













Conservative 8(3.0) 4(3.0) 4(3.0)
With consequences – – –
Cardiac tamponade
Conservative 1(0.4) – 1(0.8)
Pericardiocentesis 1(0.4) – 1(0.8)
Cardiac arrest during implantb 1(0.4) – 1(0.8)
Haemorrhage during
implant 2(0.7) 2(1.5) –
Conservative 1(0.4) – 1(0.8)
Transfer to CCU




Conservative 2(0.7) – 2(1.5)
Drainage 3(1.1) 1(0.8) 2(1.5)
Pocket haematoma
Conservative 8(3.0) 4(3.0) 4(3.0)
Re-hospitalisation/transfusiond 4(1.5) 4(3.0) 0(0)
PNS
Conservative 13(4.9) 4(3.0) 9(6.7)e
Lead revision 1(0.4) – 1(0.8)
Thrombosis v. subclavian post 
implantc
1(0.4) 1(0.4) –
Death (implant related) 1(0.4) 1(0.8) –
Total 56(20.9) 24(17.9) 32(23.9)
With consequences 21(7.8) 9(6.7) 12(9.0)
CCU coronary care unit, CS coronary sinus, LV left ventricular, 
PNS phrenic nerve stimulation.
aleading to postponement of implant or conversion to another 
entrance vein.
bdue to temporary AV block without an escape rhythm for which a 
short period of resuscitation followed by temporary pacing by the 
ICD lead after which recovery of conduction.
cfor which compression stockings and anticoagulation.
dThere was no need for re-intervention.
eP < 0.05 for comparison between de novo and upgrade procedures.
KEY MESSAGE  CRT upgrade procedures are not associated with more complications than de novo
                               CRT device implantations. 





Adjusted: for age, gender, ischaemic cardiomyopathy, atrial fibrillation,
usage of vitamin K antagonists and amiodarone
Table 4 Hazard ratio for upgrade 
versus de novo CRT implanta-
tion procedures and the risk of 
periprocedural complications, ad-
justed for differences in baseline 
characteristics between upgrade 
and de novo patients.
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Therefore, CRT upgrade procedures should be performed 
when indicated without fear for a higher complication rate. 
However, as upgrading means an additional procedure is 
needed, future research should focus on identifying patient 
characteristics that predict the necessity for upgrading to 
CRT, especially for those patients in need of upgrading 
within the life expectancy of the initial device.
Limitations
Due to the retrospective design of the study only complica-
tions properly documented in the electronic patient file were 
identified and not all baseline data were available for all 
patients. However, the advantage of the retrospective design 
is that it reflects a real-life setting of these device implanta-
tions. Furthermore, although none of the baseline characteris-
tics showed a confounding effect on the risk of periprocedural 
complications, it is possible that some data that were not col-
lected confounded the results, for instance steroid use. Finally, 
as this study shows the results of a single-centre experience, 
the results can only be applicable for a comparable centre.
Conclusion
In a device implantation centre with experienced operators, 
CRT upgrade procedures are not associated with more com-
plications nor do they seem more complex compared with 
de novo CRT implantations.
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